120.37
Illumina Inc stock is traded at $120.37, with a volume of 1.74M.
It is down -5.16% in the last 24 hours and up +2.29% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$126.92
Open:
$125.9
24h Volume:
1.74M
Relative Volume:
0.94
Market Cap:
$18.29B
Revenue:
$4.34B
Net Income/Loss:
$850.00M
P/E Ratio:
22.03
EPS:
5.4635
Net Cash Flow:
$921.00M
1W Performance:
-7.76%
1M Performance:
+2.29%
6M Performance:
+26.67%
1Y Performance:
+56.12%
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
ILMN
Illumina Inc
|
120.37 | 19.28B | 4.34B | 850.00M | 921.00M | 5.4635 |
|
TMO
Thermo Fisher Scientific Inc
|
466.26 | 174.74B | 45.20B | 6.88B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
178.80 | 126.68B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
IDXX
Idexx Laboratories Inc
|
553.66 | 45.14B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
111.30 | 32.46B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
292.13 | 29.52B | 3.17B | 642.63M | 516.49M | 10.77 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Will DRAGEN v4.5’s ML-Powered Genomics Upgrade Reshape Illumina’s (ILMN) Precision Medicine Narrative? - Yahoo Finance
Unlocking Q1 Potential of Illumina (ILMN): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance
Illumina (ILMN) Q1 earnings report preview: What to look for - MSN
Illumina Inc. stock outperforms competitors despite losses on the day - MarketWatch
Illumina, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Financial Metrics - Markets Mojo
Prenatal Testing Services Market key players 2025-2031 : Illumina Inc, Centogene NV., Revvity, Inc. etc - openPR.com
Illumina, Inc. (ILMN) Stock Analysis: Unveiling Growth Potential With A Promising Upside - DirectorsTalk Interviews
ILMN Stock Price, Quote & Chart | ILLUMINA INC (NASDAQ:ILMN) - ChartMill
Illumina, Inc. $ILMN Shares Sold by KLP Kapitalforvaltning AS - MarketBeat
Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility - Illumina
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
ILMN CLASS ACTION NOTICE: Kessler Topaz Meltzer & Check, LLP Reminds Illumina, Inc. (ILMN) Shareholders of Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm - TMX Newsfile
Universal Beteiligungs und Servicegesellschaft mbH Sells 15,739 Shares of Illumina, Inc. $ILMN - MarketBeat
Human Microbiome Sequencing Technology Market Competitive - openPR.com
Omics-Based Clinical Trials Research Report 2026: $47.78 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F - GlobeNewswire Inc.
Illumina Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Illumina (ILMN) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
AML Complexity Uncovered: - Illumina
CSR News Feed | Explore the latest corporate social responsibility news from Illumina - Illumina
Illumina Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
DNA Extraction, Isolation and Purification Market: Key Players - openPR.com
OVERSEA CHINESE BANKING Corp Ltd Decreases Stock Position in Illumina, Inc. $ILMN - MarketBeat
Gene Expression Analysis Market Set for Robust Growth to USD - openPR.com
Illumina Inc. (ILMN) – Pediatric Genomics Collaboration Bolsters Long-Term Growth Narrative Amid Mixed Historical ReturnsFast Rising Picks - Cổng thông tin điện tử tỉnh Tây Ninh
Belpointe Asset Management LLC Purchases Shares of 9,592 Illumina, Inc. $ILMN - MarketBeat
Illumina Inc. (ILMN) Launches DRAGEN v4.5 Bioinformatics Suite, Expanding Addressable Market in Genomic Research and Clinical OncologyPost Announcement - Xã Thanh Hà
ILMN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
South America Next Generation Sequencing eDNA Biomonitoring - openPR.com
Metagenomics Market Key Companies AnalysisMerck KGaA, Thermo - openPR.com
Pharmacogenomics Market Leading Companies | F. Hoffmann-la - openPR.com
Illumina Inc. stock underperforms Monday when compared to competitors - MarketWatch
Tsinghua University brings hands-on multiomics training to young scientists - Illumina
UPS, Netflix, BlackRock And A Health Care Stock On CNBC's 'Final Trades'BlackRock (NYSE:BLK), Illumina - Benzinga
Illumina, Inc. (ILMN) Stock Analysis: Balancing Innovation In Genomics With Market Volatility - DirectorsTalk Interviews
Fortis Capital Advisors LLC Invests $1.26 Million in Illumina, Inc. $ILMN - MarketBeat
Asset Management One Co. Ltd. Grows Stock Holdings in Illumina, Inc. $ILMN - MarketBeat
KBC Group NV Has $5.90 Million Stake in Illumina, Inc. $ILMN - MarketBeat
Illumina, Inc. Common Stock Ex-distribution When-Issued (ILMNV) - Minichart
Behavioral Patterns of ILMN and Institutional Flows - Stock Traders Daily
Illumina, Inc. $ILMN Shares Acquired by Cwm LLC - MarketBeat
Illumina Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Illumina (ILMN), Labcorp (LH) expand precision oncology NGS collaboration - MSN
DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows - PR Newswire
Robeco Institutional Asset Management B.V. Trims Stock Holdings in Illumina, Inc. $ILMN - MarketBeat
Illumina, Inc. (NASDAQ:ILMN) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Illumina Inc. stock (US4523271090): Why does its genomics dominance matter more now for U.S. investo - AD HOC NEWS
Illumina’s Pediatric Genomics Push Tests Long Term Growth Narrative - Yahoo Finance
Illumina partners with D3b on pediatric genomic data initiative By Investing.com - Investing.com Canada
How Investors Are Reacting To Illumina (ILMN) Board Turnover And Expanded Labcorp Precision Oncology Partnership - simplywall.st
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):